WHO ICTRP trial
Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for…
JPRN-UMIN000010050 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000010050 |
|---|---|
| Public title | Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer. |
| Scientific title | Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer. - Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer. |
| Primary sponsor | Aichi Medical University School of Medicine, Department of Tumor Immunology |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | Japan |
| Conditions | Advanced or recurrent cancer |
| Interventions | Mogamulizumab 0.1mg/kg will be administered 8 times every week. Mogamulizumab 0.5mg/kg will be administered 8 times every week. Mogamulizumab 1.0mg/kg will be administered 8 times every week. Mogamulizumab of the tolerated dose in Phase Ia… |
| Registration date | Feb 15, 2013 |
| Target size | 58 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: